Ibrahim H. Eissa, Reda G.Yousef, Hazem Elkady, Eslam B. Elkaeed, Aisha A. Alsfouk, Dalal Z. Husein, Ibrahim M. Ibrahim, Mostafa A. Asmaey, Ahmed M. Metwaly
{"title":"天然生物碱的新型抗癌衍生物,可可碱,作为EGFR抑制剂和细胞凋亡诱导剂","authors":"Ibrahim H. Eissa, Reda G.Yousef, Hazem Elkady, Eslam B. Elkaeed, Aisha A. Alsfouk, Dalal Z. Husein, Ibrahim M. Ibrahim, Mostafa A. Asmaey, Ahmed M. Metwaly","doi":"10.1007/s00214-023-03071-z","DOIUrl":null,"url":null,"abstract":"<p>The epidermal growth factor receptor (EGFR) plays a key role in the pathogenesis of cancers of different types. It has been shown that EGFR and EGF-like peptides are often overexpressed in human carcinomas and that these proteins can cause cell transformation both in vivo and in vitro. In order to design a new apoptotic EGFR inhibitor, we used the essential pharmacophoric structural properties of EGFR inhibitors. We started with the natural alkaloid, theobromine, to get a new semisynthetic N-cyclohexyl acetamide derivative (<i>T-1-NCA</i>). <i>T-1-NCA</i> was extensively examined computationally for its potential against the EGFR protein. We initially performed deep density functional theory (DFT) computations to validate its 3D structure. The electrostatic potential, global reactive indices, and total density of states anticipating a high degree of reactivity were also indicated by the DFT analyses. Second, <i>T-1-NCA</i>'s propensity to bind and inhibit the EGFR protein was investigated and verified using structure-based computational investigations such as molecular docking against EGFR<sup>WT</sup>, molecular dynamics (MD) over 100 ns, MM-GPSA, and PLIP experiments. <i>T-1-NCA</i>'s computational ADME and toxicity profiles were examined before the synthesis, and its safety and general drug-likeness were anticipated. As a consequence, <i>T-1-NCA</i> was semi-synthesized to examine the proposed design and the in silico findings. In comparison with erlotinib, <i>T-1-NCA</i> suppressed EGFR<sup>WT</sup> in vitro with an IC<sub>50</sub> value of 24.25 nM. (5.87 nM). Furthermore, <i>T-1-NCA</i> suppressed the proliferation of A549 and HCT-116 malignant cell lines with IC<sub>50</sub> values of 40.20 and 34.05 µM, respectively, as compared to erlotinib, which had IC<sub>50</sub> values of 17.13 and 17.32 µM. Interestingly, <i>T-1-NCA</i>’s selectivity indices were 3.29 and 3.89 against the two cancer cell lines indicating its general safety. Finally, the apoptotic effects of <i>T-1-NCA</i> were confirmed by flow cytometry and RT-PCR through the significant increase of the levels BAX, Casp3, and Casp9 in addition to the significant decrease of Bcl-2 level.</p>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A new anticancer derivative of the natural alkaloid, theobromine, as an EGFR inhibitor and apoptosis inducer\",\"authors\":\"Ibrahim H. Eissa, Reda G.Yousef, Hazem Elkady, Eslam B. Elkaeed, Aisha A. Alsfouk, Dalal Z. Husein, Ibrahim M. Ibrahim, Mostafa A. Asmaey, Ahmed M. Metwaly\",\"doi\":\"10.1007/s00214-023-03071-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The epidermal growth factor receptor (EGFR) plays a key role in the pathogenesis of cancers of different types. It has been shown that EGFR and EGF-like peptides are often overexpressed in human carcinomas and that these proteins can cause cell transformation both in vivo and in vitro. In order to design a new apoptotic EGFR inhibitor, we used the essential pharmacophoric structural properties of EGFR inhibitors. We started with the natural alkaloid, theobromine, to get a new semisynthetic N-cyclohexyl acetamide derivative (<i>T-1-NCA</i>). <i>T-1-NCA</i> was extensively examined computationally for its potential against the EGFR protein. We initially performed deep density functional theory (DFT) computations to validate its 3D structure. The electrostatic potential, global reactive indices, and total density of states anticipating a high degree of reactivity were also indicated by the DFT analyses. Second, <i>T-1-NCA</i>'s propensity to bind and inhibit the EGFR protein was investigated and verified using structure-based computational investigations such as molecular docking against EGFR<sup>WT</sup>, molecular dynamics (MD) over 100 ns, MM-GPSA, and PLIP experiments. <i>T-1-NCA</i>'s computational ADME and toxicity profiles were examined before the synthesis, and its safety and general drug-likeness were anticipated. As a consequence, <i>T-1-NCA</i> was semi-synthesized to examine the proposed design and the in silico findings. In comparison with erlotinib, <i>T-1-NCA</i> suppressed EGFR<sup>WT</sup> in vitro with an IC<sub>50</sub> value of 24.25 nM. (5.87 nM). Furthermore, <i>T-1-NCA</i> suppressed the proliferation of A549 and HCT-116 malignant cell lines with IC<sub>50</sub> values of 40.20 and 34.05 µM, respectively, as compared to erlotinib, which had IC<sub>50</sub> values of 17.13 and 17.32 µM. Interestingly, <i>T-1-NCA</i>’s selectivity indices were 3.29 and 3.89 against the two cancer cell lines indicating its general safety. Finally, the apoptotic effects of <i>T-1-NCA</i> were confirmed by flow cytometry and RT-PCR through the significant increase of the levels BAX, Casp3, and Casp9 in addition to the significant decrease of Bcl-2 level.</p>\",\"PeriodicalId\":1,\"journal\":{\"name\":\"Accounts of Chemical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":16.4000,\"publicationDate\":\"2023-12-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Accounts of Chemical Research\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://doi.org/10.1007/s00214-023-03071-z\",\"RegionNum\":1,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1007/s00214-023-03071-z","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
A new anticancer derivative of the natural alkaloid, theobromine, as an EGFR inhibitor and apoptosis inducer
The epidermal growth factor receptor (EGFR) plays a key role in the pathogenesis of cancers of different types. It has been shown that EGFR and EGF-like peptides are often overexpressed in human carcinomas and that these proteins can cause cell transformation both in vivo and in vitro. In order to design a new apoptotic EGFR inhibitor, we used the essential pharmacophoric structural properties of EGFR inhibitors. We started with the natural alkaloid, theobromine, to get a new semisynthetic N-cyclohexyl acetamide derivative (T-1-NCA). T-1-NCA was extensively examined computationally for its potential against the EGFR protein. We initially performed deep density functional theory (DFT) computations to validate its 3D structure. The electrostatic potential, global reactive indices, and total density of states anticipating a high degree of reactivity were also indicated by the DFT analyses. Second, T-1-NCA's propensity to bind and inhibit the EGFR protein was investigated and verified using structure-based computational investigations such as molecular docking against EGFRWT, molecular dynamics (MD) over 100 ns, MM-GPSA, and PLIP experiments. T-1-NCA's computational ADME and toxicity profiles were examined before the synthesis, and its safety and general drug-likeness were anticipated. As a consequence, T-1-NCA was semi-synthesized to examine the proposed design and the in silico findings. In comparison with erlotinib, T-1-NCA suppressed EGFRWT in vitro with an IC50 value of 24.25 nM. (5.87 nM). Furthermore, T-1-NCA suppressed the proliferation of A549 and HCT-116 malignant cell lines with IC50 values of 40.20 and 34.05 µM, respectively, as compared to erlotinib, which had IC50 values of 17.13 and 17.32 µM. Interestingly, T-1-NCA’s selectivity indices were 3.29 and 3.89 against the two cancer cell lines indicating its general safety. Finally, the apoptotic effects of T-1-NCA were confirmed by flow cytometry and RT-PCR through the significant increase of the levels BAX, Casp3, and Casp9 in addition to the significant decrease of Bcl-2 level.
期刊介绍:
Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance.
Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.